Answers are grounded in this paper and cite their sources.
Position statement outlines allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia, highlighting recommendations for first remission.
T he FMS-like tyrosine kinase 3 (FLT3) gene is mutated in 25-30% of patients with acute myeloid leukemia (AML). Because of the poor prognosis associated with FLT3-internal tandem duplication mutated AML, allogeneic hematopoietic stem-cell transplantation (SCT) was commonly performed in first complete remission.
No takes yet. Share an insight, caveat, or question.
Bazarbachi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: